Sivik Global Healthcare LLC bought a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,260,000.
Other institutional investors have also modified their holdings of the company. NorthCrest Asset Manangement LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the third quarter worth $423,000. GAMMA Investing LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 62.2% in the third quarter. GAMMA Investing LLC now owns 279 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 107 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Madrigal Pharmaceuticals by 713.2% during the third quarter. Farther Finance Advisors LLC now owns 862 shares of the biopharmaceutical company’s stock worth $434,000 after acquiring an additional 756 shares during the period. Tidal Investments LLC raised its holdings in Madrigal Pharmaceuticals by 5.2% during the second quarter. Tidal Investments LLC now owns 1,631 shares of the biopharmaceutical company’s stock worth $876,000 after purchasing an additional 80 shares in the last quarter. Finally, Engineers Gate Manager LP purchased a new position in Madrigal Pharmaceuticals during the second quarter worth about $709,000. 98.50% of the stock is owned by institutional investors and hedge funds.
Madrigal Pharmaceuticals Price Performance
Shares of MDGL stock traded down $15.90 during midday trading on Tuesday, reaching $451.25. 102,308 shares of the company traded hands, compared to its average volume of 330,816. The firm’s 50 day simple moving average is $519.47 and its two-hundred day simple moving average is $518.32. The firm has a market cap of $10.42 billion, a PE ratio of -35.01 and a beta of -1.04. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94. Madrigal Pharmaceuticals, Inc. has a 1-year low of $393.61 and a 1-year high of $615.00.
Insider Activity
In other Madrigal Pharmaceuticals news, CEO William Sibold sold 6,362 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the sale, the chief executive officer owned 202,967 shares of the company’s stock, valued at $108,707,095.53. This represents a 3.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $514.97, for a total transaction of $341,940.08. Following the completion of the sale, the general counsel owned 11,474 shares in the company, valued at $5,908,765.78. This represents a 5.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 12,247 shares of company stock valued at $6,581,182 over the last 90 days. 17.60% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the company. Wells Fargo & Company assumed coverage on Madrigal Pharmaceuticals in a research report on Monday, July 27th. They set an “overweight” rating and a $685.00 target price on the stock. Barclays reduced their price target on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. Citigroup assumed coverage on Madrigal Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a “buy” rating and a $725.00 price target on the stock. Wolfe Research raised Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price objective on the stock in a report on Tuesday, August 4th. Finally, The Goldman Sachs Group began coverage on Madrigal Pharmaceuticals in a report on Thursday, September 24th. They set a “buy” rating and a $704.00 price objective on the stock. Fifteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $710.20.
View Our Latest Research Report on MDGL
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for chronic liver diseases. The company’s primary focus is metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease that can lead to significant liver fibrosis, cirrhosis and other complications.
Madrigal’s lead product, Rezdiffra (resmetirom), is an oral thyroid hormone receptor beta agonist. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH accompanied by moderate to advanced liver fibrosis.
Featured Stories
- Five stocks we like better than Madrigal Pharmaceuticals
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
